What Is Madecassoside? A Complete Scientific Guide to Centella Asiatica's Most Powerful Barrier Component
What Is Madecassoside? A Complete Scientific Guide to Centella Asiatica's Most Powerful Barrier Component
Key Scientific Facts
- Madecassoside holds the highest anti-inflammatory potential among Centella asiatica's four primary active triterpenoids
- It suppresses pro-inflammatory cytokine release by inhibiting the NF-κB signaling pathway
- TGF-β1 activation increases fibroblast proliferation and collagen type I–III synthesis
- In vitro studies show madecassoside supports tight junction integrity and reduces TEWL
- Unlike asiaticoside, it carries an extra hydroxyl group, which enhances its stability and bioavailability
- The CIRÈLL formulation combines madecassoside with the ectoin and ceramide system to deliver multi-layered barrier support
Expert Support for Your Skin Barrier
Reach out directly with your questions about madecassoside and the CIRÈLL formulation.
Contact Us on WhatsAppContents
- Centella Asiatica and Its Active Components
- Madecassoside's Chemical Structure and Stability
- The Anti-Inflammatory Mechanism: NF-κB Inhibition
- Collagen Synthesis: The TGF-β Pathway
- TEWL Reduction and Barrier Strengthening
- Madecassoside vs. Asiaticoside
- Which Skin Conditions Does It Benefit?
- Protocol for Sensitive and Rosacea-Prone Skin
- Combination With Other Actives
- Concentration and Label-Reading Guide
- Conclusion: Madecassoside With CIRÈLL
Madecassoside is a triterpenoid glycoside derived from the Centella asiatica plant. Through its direct effect on the NF-κB inflammatory pathway and collagen synthesis, it functions as both a soothing agent and a repair-supporting active.
Centella Asiatica and Its Active Components
Centella asiatica — the tropical plant popularly known as "gotu kola" or "tiger grass" — has been used in traditional Asian medicine for centuries as a wound healer and skin restorer. Yet science's genuine understanding of this plant only became possible in the mid-20th century, with the isolation of its active components.
The four main triterpenoid components known to be effective are: asiaticoside, madecassoside, asiatic acid, and madecassic acid. These compounds make up roughly 1–8% of Centella asiatica's total dry weight and act through distinct mechanisms.
| Component | Type | Primary Effect | Stability | Bioavailability |
|---|---|---|---|---|
| Madecassoside | Triterpenoid glycoside | Anti-inflammatory, barrier repair | High | High |
| Asiaticoside | Triterpenoid glycoside | Wound healing, collagen | Moderate | Moderate |
| Asiatic acid | Free triterpene acid | Collagen synthesis, antioxidant | Low | Low |
| Madecassic acid | Free triterpene acid | Anti-inflammatory | Low | Low |
The two components most commonly used in cosmetic formulations are asiaticoside and madecassoside. However, recent research shows that madecassoside delivers superior results particularly in sensitive and inflammation-prone skin.
Madecassoside's Chemical Structure and Stability
Chemically, madecassoside is the glycoside form of madecassic acid. The molecule consists of a triterpene aglycone core (madecassic acid) bonded to three sugar units (two glucose and one rhamnose). This structure gives madecassoside a distinguishing chemical property relative to asiaticoside: an extra hydroxyl group.
This additional hydroxyl group explains why madecassoside is preferred in cosmetic formulations:
- Higher hydrophilic character: better solubility in aqueous formulations
- Enhanced bioavailability: improved penetration into the stratum corneum
- Thermal stability: greater resilience to manufacturing processes
- pH stability: remains active across a wide pH range (pH 4–7)
The Anti-Inflammatory Mechanism: NF-κB Inhibition
At the center of madecassoside's anti-inflammatory effect lies inhibition of the NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) signaling pathway. NF-κB is a transcription factor that controls the transcription of pro-inflammatory mediators such as IL-1β, TNF-α, IL-6, and COX-2.
Under normal conditions, NF-κB remains inactive in the cytoplasm, bound to the inhibitory protein IκB. When an irritant factor (UV radiation, an allergen, bacteria) triggers IκB phosphorylation and proteasomal degradation, NF-κB is released, translocates to the nucleus, and initiates expression of inflammatory genes.
Madecassoside blocks multiple points of this processBylka et al., 2013:
- Prevents IκB phosphorylation (IKK kinase inhibition)
- Blocks NF-κB's translocation to the nucleus
- Lowers pro-inflammatory cytokine (IL-1β, IL-6, TNF-α) mRNA levels
- Suppresses COX-2 expression → reduces prostaglandin E2 production
| Inflammatory Mediator | Madecassoside's Effect | Clinical Significance |
|---|---|---|
| IL-1β | mRNA expression reduced by 40–60% | Acute inflammation suppressed |
| TNF-α | Release reduced by 35–50% | Chronic inflammation controlled |
| IL-6 | Protein levels decrease | Rosacea redness diminishes |
| COX-2 | Expression suppressed | Sensitive skin reactivity decreases |
| Prostaglandin E2 | Production decreases | Burning and itching are relieved |
Collagen Synthesis: The TGF-β Pathway
Madecassoside does not merely suppress inflammation — it also activates a genuinely active tissue repair and renewal pathway. This effect operates through the TGF-β1 (Transforming Growth Factor Beta-1) signaling pathway.
"TGF-β1 is a powerful stimulant for dermal fibroblasts: it activates fibroblasts, increases their proliferation, and raises synthesis of both collagen type I and type III. Madecassoside accelerates this process by potentiating TGF-β1 signaling."
Collagen Type I
Forms the dermis's structural framework. Following madecassoside application, type I procollagen synthesis in fibroblast cultures increases by 40–70%. Renewal of this collagen type — depleted by aging and barrier damage — is critical for skin firmness.
Collagen Type III
Also known as "baby collagen," type III predominates in the early phase of wound healing before being replaced by type I. Madecassoside supports both acute repair (type III) and long-term renewal (type I) processes.
TEWL Reduction and Barrier Strengthening
Transepidermal water loss (TEWL) is the most objective indicator of skin barrier health. Madecassoside's effect on TEWL operates through multiple mechanisms:
1. Tight junction proteins: Madecassoside increases expression of tight junction proteins such as claudin-1 and occludin. These proteins act as "cement" binding keratinocytes together and block passive water transit.
2. Filaggrin induction: Filaggrin, a precursor of the natural moisturizing factor (NMF), is an essential protein for stratum corneum integrity. Madecassoside supports keratinocyte differentiation by increasing filaggrin mRNA expression.
3. The anti-inflammatory pathway: Inflammation directly damages tight junction proteins and suppresses ceramide synthesis. By reducing inflammation, madecassoside indirectly protects barrier function.
Madecassoside vs. Asiaticoside: Which Is Superior?
Both components are derived from Centella asiatica and act through similar mechanisms. However, notable differences matter when choosing between them for skincare.
Madecassoside
- Extra OH group → higher polarity
- Better solubility in aqueous formulations
- Stronger anti-inflammatory effect (NF-κB)
- More stable formulation (thermal and pH stability)
- More frequently preferred for sensitive skin and rosacea
Asiaticoside
- Slightly more direct effect on collagen synthesis
- More extensive long-term use evidence in wound healing
- Oil-solubility advantage (emollient formulations)
- More studied in hypertrophic scar and keloid research
- Common in general anti-aging formulations
In summary, madecassoside may be preferred when inflammation suppression and barrier repair are the priority; asiaticoside when fibrosis inhibition and scar prevention are the priority. The most comprehensive approach is a full Centella asiatica extract formulation that uses both togetherPaocharoen, 2010.
Which Skin Conditions Does It Benefit?
Suppresses IL-6 and TNF-α to reduce redness and flushing. Recommended as a barrier-strengthening component in rosacea care.
Lowers reactivity through NF-κB inhibition. Ideal within fragrance-free formulations for sensitive skin.
Accelerates barrier repair through increased tight junction proteins and filaggrin. A first choice following irritation.
Interrupts inflammation before post-inflammatory hyperpigmentation sets in, reducing the risk of scarring.
Supports atopic skin management by supporting filaggrin production and indirectly counteracting S. aureus colonization.
An ideal repair active for acid users to offset the barrier weakening that follows AHA/BHA use.
Application Protocol for Sensitive and Rosacea-Prone Skin
Combination With Other Actives
| Active | Compatibility With Madecassoside | Combined Effect |
|---|---|---|
| Ectoin | Excellent | Together they block both inflammation and environmental stress; an ideal pair for sensitive skin |
| Panthenol (B5) | Excellent | Panthenol accelerates keratinocyte repair while madecassoside interrupts inflammation; a synergistic pairing |
| Ceramide | Excellent | Madecassoside strengthens tight junctions while ceramide repairs the lipid matrix; a dual barrier safeguard |
| Niacinamide | Good | Both strengthen the barrier; niacinamide adds sebum control |
| Retinol | Good (timing matters) | Madecassoside counters retinol dermatitis; a morning-madecassoside/evening-retinol routine works well |
| AHA/BHA | Careful use | Not simultaneously; an evening-AHA/BHA, morning-madecassoside logic is appropriate |
Concentration and Label-Reading Guide
Madecassoside appears at varying concentrations across products on the market. Clinical studies suggest a minimum concentration of 0.1% is required for a measurable effect. However, in products containing a full Centella asiatica extract, assessment based on total triterpenoid content is more meaningful.
| Label Information | Meaning | Estimated Strength |
|---|---|---|
| Madecassoside 0.1–0.3% | Low dose — for soothing purposes | Mild effect |
| Madecassoside 0.5–1.0% | Moderate dose — clinical evidence range | Noticeable effect |
| Centella asiatica extract, 80% triterpenoids | Standardized extract — guaranteed total triterpenoid content | Strong effect |
| "Cica" (general marketing term) | Generally a Centella extract, concentration unspecified | Variable |
| Asiaticoside (no madecassoside) | Single component only; an incomplete formulation | Partial effect |
Conclusion: Madecassoside and the CIRÈLL Formulation
Although madecassoside enjoys wide attention under the "cica" label in the cosmetics world, many products use this name in ways disconnected from scientific evidence. A genuinely effective madecassoside application requires the correct concentration, a suitable formulation pH, and a complementary active combination.
CIRÈLL uses madecassoside within its formulation as part of the multi-layered architecture of barrier repair. The Biomimetic TriBarrier System — ceramide NP+AP+EOP, cholesterol, and fatty acids — reinforces from the lipid side the tight junctions that madecassoside strengthens. Together with ectoin and panthenol, CIRÈLL suppresses inflammation while simultaneously repairing both barrier lipids and the protein scaffold. Science's integrated approach is CIRÈLL's design philosophy.
Frequently Asked Questions
How long does madecassoside take to show effect?
The initial soothing effect is generally felt within 1–2 weeks. TEWL reduction and barrier strengthening require 4–8 weeks of regular use. Clinical studies measured the most pronounced results at week 8.
What is Centella asiatica?
Centella asiatica (Gotu Kola / Asiatic pennywort) is a plant used for centuries in traditional Asian medicine as a wound healer. Its efficacy in skincare derives from the triterpenoid compounds it contains — madecassoside, asiaticoside, and madecassic acid.
What is Centella asiatica used for?
Centella asiatica strengthens the skin barrier, accelerates wound and scar healing, supports collagen synthesis, and soothes irritation. These effects are primarily explained by the plant's madecassoside and asiaticoside compounds stimulating collagen synthesis and suppressing inflammation.
What are Centella asiatica's benefits for skin?
Centella asiatica provides soothing, repairing, and antioxidant benefits for skin: it reduces redness, supports barrier function, promotes collagen production, and lowers transepidermal water loss (TEWL). It is therefore frequently chosen for sensitive, rosacea-prone, and barrier-compromised skin.
Can madecassoside be used every day?
Yes, madecassoside is suitable for daily use. Morning and evening application is recommended. Even in sensitive skin, the risk of side effects is extremely low.
What is the difference between asiaticoside and madecassoside?
Both are derived from Centella asiatica, but madecassoside has higher hydrophilic character and stability due to an extra hydroxyl group. Its anti-inflammatory potential is stronger; it is preferred for sensitive skin and rosacea.
Can madecassoside be used with retinol?
Yes, though alternating morning/evening use is recommended rather than simultaneous application. Madecassoside is effective in managing the irritation caused by retinol.
Does a "Cica" cream contain madecassoside?
Not always. "Cica" is a marketing term meaning the product contains Centella asiatica extract; however, the specific triterpenoid concentration in the formula may not be disclosed. When reading the label, look for "madecassoside" or "asiaticoside" specifically.
How should madecassoside be used for rosacea?
Regular morning and evening use alongside SPF is recommended. During inflammatory periods (redness, burning), it can be applied twice daily. Avoiding trigger factors strengthens madecassoside's effect.
Is madecassoside safe during pregnancy?
Its overall safety profile is favorable, and systemic absorption from topical application is minimal. However, consulting your dermatologist before introducing any new product during pregnancy is recommended.
Does madecassoside worsen acne?
No — quite the opposite. Through its anti-inflammatory effect, madecassoside suppresses the inflammatory phase of acne lesions and reduces post-inflammatory redness.
Is madecassoside suitable for oily skin?
Yes. Madecassoside is a non-comedogenic active that reduces inflammation without disrupting barrier balance in oily skin. It can be preferred in lightweight formulations such as serums and gels.
What concentration of madecassoside should products contain?
Clinical evidence shows the 0.1–1.0% range to be effective. In standardized Centella asiatica extracts, assessment can also be based on total triterpenoid content (40–80%).
Can madecassoside be used together with niacinamide?
Yes, this combination reinforces both anti-inflammatory and barrier-strengthening properties. Niacinamide additionally provides sebum regulation and brightening.
Can madecassoside share a routine with AHA/BHA?
Rather than applying simultaneously, plan for evening AHA/BHA and morning madecassoside on acid days. Madecassoside accelerates barrier repair following acid use.
How does the madecassoside-panthenol combination work?
Panthenol increases keratinocyte proliferation while madecassoside interrupts inflammation; together they synergistically accelerate the rate of repair. These two actives are highly compatible.
Can madecassoside be used in eczema?
Yes, particularly during the remission phase it can be used in eczema care. Dermatological guidance should be sought during an active flare.
Is madecassoside more effective combined with ectoin?
This combination is under clinical investigation, and a strong synergy is expected at the mechanistic level: ectoin manages osmotic/environmental stress while madecassoside blocks the NF-κB pathway. CIRÈLL uses this combination in its formulation.
Scientific Sources
- Bylka W, Znajdek-Awizen P, Studzinska-Sroka E, Brzezinska M. Centella asiatica in cosmetology. Adv Dermatol Allergol. 2013;30(1):46–49. PMID: 24278045
- Shukla A, Rasik AM, Jain GK, et al. In vitro and in vivo wound healing activity of asiaticoside isolated from Centella asiatica. J Ethnopharmacol. 1999;65(1):1–11. PMID: 10350364
- Paocharoen V. The efficacy and side effects of oral Centella asiatica extract for wound healing promotion in diabetic wound patients. J Med Assoc Thai. 2010;93(Suppl 7):S166–S170.
- Lee J, Jung E, Kim Y, et al. Asiaticoside induces human collagen I synthesis through TGFβ receptor I kinase (TβRI kinase)-independent Smad signaling. Planta Med. 2006;72(4):324–328.
- Chong NJ, Aziz Z. A systematic review of the efficacy of Centella asiatica for improvement of the signs and symptoms of chronic venous insufficiency. Evid Based Complement Alternat Med. 2013;2013:627182.
- Gohil KJ, Patel JA, Gajjar AK. Pharmacological review on Centella asiatica: a potential herbal cure-all. Indian J Pharm Sci. 2010;72(5):546–556.
- Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol. 2005;125(2):183–200. PMID: 16098026
- Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17(12):1063–1072. PMID: 19043850
- Rawlings AV, Harding CR. Moisturization and skin barrier function. Dermatol Ther. 2004;17(Suppl 1):43–48. PMID: 14728698
- Meckfessel MH, Brandt S. The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products. J Am Acad Dermatol. 2014;71(1):177–184. PMID: 24656726
CIRÈLL's Choice of Madecassoside: Can Repair Happen Without Inflammation?
Chronic low-grade inflammation — "inflammaging" — is both a source and a consequence of barrier damage. Madecassoside was selected within the CIRÈLL formulation to break this cycle.
- NF-κB inhibition: the master switch of the inflammatory cascade is turned off — both IL-1β and TNF-α decrease.
- TGF-β1 activation increases fibroblast collagen synthesis — repair-material production is increased.
- Collagen I and III synthesis: it does not merely soothe, it delivers genuine structural renewal.
- Works through multiple mechanisms simultaneously in sensitive, rosacea-prone, atopic, and barrier-damaged skin.
At CIRÈLL, madecassoside is not treated as "a soothing agent like aloe vera" — it is a pharmacological active that interrupts inflammation to prepare the ground for repair.